AZATHIOPRINE TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

AZATHIOPRINE

Mevcut itibaren:

SANIS HEALTH INC

ATC kodu:

L04AX01

INN (International Adı):

AZATHIOPRINE

Doz:

50MG

Farmasötik formu:

TABLET

Kompozisyon:

AZATHIOPRINE 50MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

IMMUNOSUPPRESSIVE AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0101830001; AHFS:

Yetkilendirme durumu:

CANCELLED POST MARKET

Yetkilendirme tarihi:

2017-07-31

Ürün özellikleri

_____________________________________________________________________________________
_AZATHIOPRINE Product Monograph _
_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
AZATHIOPRINE
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
SANIS HEALTH INC.
333 CHAMPLAIN ST.
DIEPPE, NEW BRUNSWICK
DATE OF PREPARATION:
E1A 1P2
July 7, 2015
CONTROL #: 184965
_____________________________________________________________________________________
_AZATHIOPRINE Product Monograph _
_Page 2 of 25_
TABLE OF CONTENTS
PART I:
HEALTH PROFESSIONAL INFORMATION
..............................................
3
SUMMARY PRODUCT INFORMATION
......................................................
3
INDICATIONS AND CLINICAL USE
............................................................
3
CONTRAINDICATIONS
.................................................................................
3
WARNINGS AND PRECAUTIONS
................................................................
4
ADVERSE REACTIONS
..................................................................................
8
DRUG INTERACTIONS
..................................................................................
10
DOSAGE AND ADMINISTRATION
..............................................................
12
OVERDOSAGE
................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................
13
STORAGE AND STABILITY
..........................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.......................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING .............................
15
PART II: SCIENTIFIC INFORMATION
........................................................................
16
PHARMACEUTICAL INFORMATION
..........................................................
16
CLINICAL TRIALS
..........................................................................................
16
TOXICOLOGY
.....................